Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | PREP | P48147 | 4/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18068155 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL18018350 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL384513 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL2214614 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL23668781 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL15213647 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL24113163 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL19064732 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL21530145 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL2214621 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| EP-3589628-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3985002-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240327434-A1 | FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| EP-2475668-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011029915-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| EP-2272825-A2 | N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| EP-2170939-A1 | KALLIKREIN 7 MODULATORS | Novartis Ag (CH) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009000878-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| EP-1559710-A2 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use | Bristol-Myers Squibb Company (US) | 2005-08-03 | — | — | EP | disclosed |
| US-6395767-B2 | ANTIDIABETIC AGENTS; SAXAGLIPTIN | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059163-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | NR1H2 439/4885HSD17B10 3025/4885CHRM2 4837/4885 |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | DPP4, DPP3, DPP7 | NR1H2 733/4885HSD17B10 358/4885CHRM2 3161/4885 |
| US-20240327434-A1 | FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | KRAS, NRAS, HRAS | NR1H2 531/4885HSD17B10 3041/4885CHRM2 4865/4885 |
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | CFD, CFH, TFPI | NR1H2 1556/4885HSD17B10 1384/4885CHRM2 4846/4885 |
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | NR1H2 3243/4885HSD17B10 1415/4885CHRM2 4480/4885 |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | NR1H2 3573/4885HSD17B10 804/4885CHRM2 4652/4885 |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | NR1H2 519/4885HSD17B10 1063/4885CHRM2 3139/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | NR1H2 767/4885HSD17B10 991/4885CHRM2 2731/4885 |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | NR1H2 112/4885HSD17B10 478/4885CHRM2 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.